Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Date:10/30/2008

ast 20 months in the trial, and the most advanced patients began completing the two-year trial in the first half of September 2008.

-- Completed enrollment in the Phase 2b clinical trial of APD125, Arena's internally discovered oral drug candidate intended to reduce insomnia symptoms and improve sleep maintenance and quality. This randomized, double-blind, placebo-controlled subjective study enrolled 744 patients in about 65 clinical sites in the United States.

-- Announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatment of arterial thrombosis and other related conditions. In the Phase 1b trial, APD791 was generally well tolerated and dose-dependent inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated. APD791 was rapidly absorbed and exposures were related to dose.

Updated 2008 Financial Guidance

Arena also reported that its updated financial guidance is for year ending 2008 cash, cash equivalents and short-term investments to total approximately $115 million. This represents a decrease from Arena's previous guidance of year ending 2008 cash of approximately $160 million. The decrease is due to Arena's election to satisfy entirely in cash the notice from the holders to redeem all outstanding shares of its Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock. Arena expects to redeem such shares on November 13, 2008 for approximately $55.8 million. The decrease in cash guidance is partially offset by a decrease in planned expenses in external clinical and preclinical study fees and expenses.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the third quarter 2008 financial results and to provide a corporate update today, Thursday, Octobe
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
2. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
3. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
4. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
6. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
9. Arena Pharmaceuticals Announces Public Offering of Common Stock
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... could prove useful in treating small cell lung cancer - ... the Cancer Research UK Manchester Institute, based at The University ... teamed up with experts at AstraZeneca, as part of a ... as AZD3965 - on small cell lung cancer cells. , ... , also helps identify which patients are most likely to ...
(Date:7/9/2014)... If you think winning is one of the key determinants ... along with other mental bonuses ranked near the bottom of ... of 11 big fun factors, according to a new study. ... it comes to the "fun" factor, very little research had ... this elusive conceptuntil now. , The results of this study ...
(Date:7/9/2014)... reveal that sudden, acute episodes of low back pain ... humidity, air pressure, wind direction and precipitation. Findings published ... of the American College of Rheumatology (ACR), indicate that ... higher wind speed or wind gusts, but was not ... Organization (WHO) nearly everyone experiences low back pain at ...
(Date:7/9/2014)... Boston, MA -- Vasectomy was associated with a small ... for advanced or lethal prostate cancer according to a ... The researchers found that the association remained even among ... risk of lethal cancer cannot be explained by diagnostic ... to date to look at the link between vasectomy ...
(Date:7/9/2014)... told she had an aneurysm, she figured an invasive brain ... was devastated," said Wakulich, who is 56 years old and ... serious diagnosis. Then I met Dr. Bernard Bendok who told ... procedure. It was something I didn,t even know was an ... clinical trial to evaluate the safety and effectiveness of the ...
Breaking Medicine News(10 mins):Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2
... Chocolate Milk Can Help Athletes Refuel ... And Earn ... ... scored a,valuable spot on and off the court. Studies suggest the unique ... body after,exercise, making it an ideal post-exercise choice. Now high school teams,who ...
... more fruits and vegetables , , WEDNESDAY, March 12 (HealthDay ... healthy eating habits in children aged 2 to 5, ... at the University of Miami Miller School of Medicine, ... to eight subsidized child-care centers in Miami Dade County. ...
... Klein Renowned for IVF Success, NEWBURGH, N.Y., ... affiliate of The Mount Sinai Hospital, is proud ... with the addition of,Reproductive Endocrinologist Jeffrey Klein, M.D. ... director of the Westchester division of,Reproductive Medicine Associates ...
... , A researcher from the Physical Anthropological Laboratory ... the most complete database today to identify human remains ... computerised techniques for facial reconstruction. This method will reduce ... it will avoid the need to perform an expensive, ...
... donating stock to establish corporate foundation; Community ... helps care for the aging in Bay Area, ... is pleased to,announce its participation as the 200th ... to engaging high-growth,companies in corporate citizenship and philanthropic ...
... 12 Managed Health Care,Associates, Inc. (MHA) announces ... Member Study, the results of which will be,revealed ... 2008 in Las Vegas,Nevada., The report was ... 2007,and examined self-reported data for key operational elements ...
Cached Medicine News:Health News:Chocolate Milk + Exercise = A Winning Team 2Health News:Chocolate Milk + Exercise = A Winning Team 3Health News:Chocolate Milk + Exercise = A Winning Team 4Health News:Preschool Intervention Curbed Trend Toward Obesity 2Health News:Preschool Intervention Curbed Trend Toward Obesity 3Health News:SLCH Brings Infertility Specialist to Region 2Health News:Body identification by facial reconstruction will cost less time and money 2Health News:Caring.com Joins Entrepreneurs Foundation as 200th Member 2Health News:MHA to Release Findings of Independent Long Term Care Member Study 2
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ --,CuraGen ... interim clinical data on intravenous belinostat,(PXD101), a ... treatment of cancer, are expected to be ... One oral and one poster presentation discussing ...
... WIRE)--Apr 18, 2007 - Critical,Therapeutics, Inc. (Nasdaq: ... a role in chronic inflammatory,autoimmune disease for ... mediator and nuclear DNA-binding protein, will be,published ... Immunology. The,publication demonstrates that HMGB1 is part ...
Cached Medicine Technology:CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5
... The Thumper Board provides optimum head hyperextension, open ... intubation easier. Placed at strategic locations throughout ... CPR to be started immediately, and easy conversion ... patient application can be done in less than ...
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
Medicine Products: